UCL  IRIS
Institutional Research Information Service
UCL Logo
Please report any queries concerning the funding data grouped in the sections named "Externally Awarded" or "Internally Disbursed" (shown on the profile page) to your Research Finance Administrator. Your can find your Research Finance Administrator at https://www.ucl.ac.uk/finance/research/rs-contacts.php by entering your department
Please report any queries concerning the student data shown on the profile page to:

Email: portico-services@ucl.ac.uk

Help Desk: http://www.ucl.ac.uk/ras/portico/helpdesk
Publication Detail
B-lymphocyte depletion therapy in rheumatoid arthritis and other autoimmune disorders
  • Publication Type:
    Journal article
  • Publication Sub Type:
    Article
  • Authors:
    Edwards JC, Leandro MJ, Cambridge G
  • Publication date:
    08/2002
  • Pagination:
    824, 828
  • Journal:
    Biochemical Society Transactions
  • Volume:
    30
  • Issue:
    4
  • Print ISSN:
    0300-5127
  • Keywords:
    antibodies, Antibodies, Monoclonal, Antibody, Arthritis, Arthritis, Rheumatoid, Autoantibodies, autoimmune, Autoimmune Diseases, B Lymphocyte, B-lymphocyte, B-Lymphocyte Subsets, B-Lymphocytes, clinical, DEPLETION, DISORDER, Disorders, EFFICACY, GENERATION, IM, immunology, IMMUNOSUPPRESSION, IMPROVEMENT, LA, LEVEL, Lymphocyte Depletion, May, MECHANISM, Methods, Other, PATHOGENESIS, PERSISTENCE, RANGE, RELEVANT, Review, Rheumatoid arthritis, RHEUMATOID-ARTHRITIS, rituximab, SUBSETS, support, therapeutic use, THERAPIES, therapy, Treatment Outcome
  • Notes:
    UI - 22183950 DA - 20020828 IS - 0300-5127 LA - eng PT - Journal Article PT - Review PT - Review, Tutorial RN - 0 (Antibodies, Monoclonal) RN - 0 (rituximab) SB - IM
Abstract
B-lymphocyte depletion therapy is being explored in a wide range of autoimmune disorders. In many, there is early evidence for efficacy, and immunosuppression has not been a major problem. The mechanism of action is unclear, but appears to be consistent with the lowering of autoantibody levels, where relevant antibodies are quantifiable. An interesting finding is the persistence of clinical improvement for periods of 1 year or more after B-lymphocyte return, which supports the concept that stochastic generation of rare pathogenic B-lymphocyte subsets may be a rate-limiting step in pathogenesis
Publication data is maintained in RPS. Visit https://rps.ucl.ac.uk
 More search options
UCL Researchers
Author
Inflammation
Author
Div of Medicine
University College London - Gower Street - London - WC1E 6BT Tel:+44 (0)20 7679 2000

© UCL 1999–2011

Search by